-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Desidustat in Chemotherapy Induced Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Desidustat in Chemotherapy Induced Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Desidustat in Chemotherapy Induced Anemia Drug Details: Desidustat (Oxemia) is an erythropoietin-stimulating...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Hypertriglyceridemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Hypertriglyceridemia Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Liver Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Liver Diseases report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Liver Diseases Drug Details: Saroglitazar (lipaglyn) is the first...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Nivolumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Cholestasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Cholestasis Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Endometriosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Endometriosis - Drugs In Development, 2023’, provides an overview of the Endometriosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Varicella Zoster (HHV-3) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Drugs In Development, 2023’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Rabies – Drugs In Development, 2023
Global Markets Direct’s, ‘Rabies - Drugs In Development, 2023’, provides an overview of the Rabies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...